Document is current
Any future updates will be listed below
-
Authors
Bazinet, Alexandre
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Wei, Yue https://orcid.org/0000-0002-2288-8405
Bataller, Alex https://orcid.org/0000-0002-6085-2745
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Arani, Naszrin
Darbaniyan, Faezeh
Chien, Kelly https://orcid.org/0000-0001-6024-1613
Hammond, Danielle https://orcid.org/0000-0002-6017-2264
Bouligny, Ian https://orcid.org/0000-0002-4274-4249
Kanagal-Shamanna, Rashmi https://orcid.org/0000-0001-7829-5249
Thongon, Natthakan
Tang, Guilin https://orcid.org/0000-0002-9482-4806
Urrutia, Samuel
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
DiNardo, Courtney https://orcid.org/0000-0001-9003-0390
Daver, Naval https://orcid.org/0000-0001-7103-373X
Short, Nicholas https://orcid.org/0000-0002-2983-2738
Issa, Ghayas https://orcid.org/0000-0002-4339-8683
Pemmaraju, Naveen https://orcid.org/0000-0002-1670-6513
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Wang, Sa A. https://orcid.org/0000-0001-9385-9911
Wang, Wei https://orcid.org/0000-0001-6821-4556
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Bueso-Ramos, Carlos
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Medeiros, L. Jeffrey https://orcid.org/0000-0001-6577-8006
Kantarjian, Hagop
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Montalban-Bravo, Guillermo https://orcid.org/0000-0002-4533-5176
- License Information
-
More Information
Article History
Received: 21 April 2025
Revised: 18 June 2025
Accepted: 9 July 2025
First Online: 21 July 2025
Competing interests
: SL declares research support from Amgen and Astellas and consulting fees from AbbVie, AlphaSight, Arima, Blueprint Medicine, BMS, Caris, Daiichi-Sankyo, Gerson Lehrman Group, Guide Point, Immunogen, Kura Oncology, QualWorld, Recordati, Servier, Stemline Syndax, and Tempus AI. KS declares honoraria from Otsuka Pharma and a consultancy fee from Pfizer Japan. HK declares research support from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer, honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda, and an advisory role with Actinium. GG-M declares support from and an advisory role with Celgene Corporation, Astex, and Amphivena, and grant/research support 15 from Helsinn, Novartis, AbbVie, Onconova, H3 Biomedicine, and Merck. The rest of the authors declare no competing financial interests.
: All methods described in this manuscript were performed in accordance with the relevant guidelines and regulations. The study protocols reported in this manuscript were conducted in accordance with the Declaration of Helsinki. Patients who donated bone marrow aspiration samples provided written consent in accordance with the biobanking study protocol, which was approved by the University of Texas MD Anderson Cancer Center Review Board under protocol LAB-01-743. All patients provided written informed consent.
